Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Roland Magnusson / Shutterstock.com LogicBio (NASDAQ: LOGC ) stock is seeing massive gains on Monday following news that AstraZeneca (NASDAQ: AZN ) subsidiary Alexion is acquiring the clinical-stag...
LogicBio ( NASDAQ: LOGC ) gained ~648% pre-market Monday after Alexion, a unit of AstraZeneca ( AZN ) announced an agreement to acquire the U.S.-based genetic medicine company for $2.07 per share in cash. The Lexington, MA company boasts a genome editing platform, ...
Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine PR Newswire LogicBio acquisition to build on current collaborations and advancements in genomic medicine LEXING...
LogicBio® Therapeutics Announces Pre-Clinical Results for mLB-001 Published in Peer-reviewed Journal PLOS ONE PR Newswire Single intravenous administration of mLB-001 in neonatal or adult MMA mice correlated with prevention of severe weight loss and mortality when...
LogicBio press release ( NASDAQ: LOGC ): Q2 GAAP EPS of -$0.15. Revenue of $3.2M (+300.0% Y/Y). As of June 30, 2022, the company had cash and cash equivalents of $38.8M as compared to $53.5M as of Dec. 31, 2021 For further details see: Log...
LogicBio Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update PR Newswire - Interim data from SUNRISE trial in four pediatric patients showed detectable levels of ALB-2A biomarker demonstrating site-specific gene insertion and protei...
LogicBio® Therapeutics to Present at H.C. Wainwright Global Investment Conference PR Newswire LEXINGTON, Mass. , May 17, 2022 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that pre...
LogicBio press release (NASDAQ:LOGC): Q1 GAAP EPS of -$0.20. Revenue of $2.81M. For further details see: LogicBio GAAP EPS of -$0.20, revenue of $2.81M
LogicBio Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Business Updates PR Newswire –FDA lifted clinical hold on SUNRISE trial in pediatric patients with methylmalonic acidemia –Interim clinical data from ...
LogicBio Therapeutics Announces Upcoming Presentations on GeneRide Development Candidate and Multiple Advancements in AAV Manufacturing Processes at ASGCT Annual Meeting PR Newswire - GeneRide ® LB-401 preclinical data in HT1 demonstrated substantial and d...
News, Short Squeeze, Breakout and More Instantly...
LogicBio Therapeutics Inc. Company Name:
LOGC Stock Symbol:
NASDAQ Market:
LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates PR Newswire - Pre-clinical results published in PLOS ONE demonstrating a single intravenous administration of mLB-001 in neonatal or adult MMA mice correlated with preventi...
NEW YORK, NY / ACCESSWIRE / October 20, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: KnowBe4, Inc. (NASDAQ:KNBE)'s s...
NEW YORK, NY / ACCESSWIRE / October 16, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: LogicBio Therapeutics, Inc. (NASD...